Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients ...

KY1005 – now renamed amlitelimab – is one of a handful of new drugs targeting OX40 ligand, an immune system regulator delivered by intravenous infusion once every 28 days. It is also being ...

A new drug class that is currently being investigated is the OX40 inhibitor, which targets OX40 receptors and ligands. OX40 inhibitors may be promising as AD treatments, as key opinion leaders ...

KY1005 works by bonding to the OX40-Ligand (OX40-L), which forms an important part of the process that activates the immune system. Interaction between OX40-L and its binding partner OX40 have ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD: Paris Wednesday, April 16, 2025, 10:00 Hrs [IST] Sanofi shared new pro ...

French pharma major Sanofi (Euronext: SAN) has shared new progress from its mid- to late-stage respiratory pipeline. The Paris-based company has presented new Phase II data on amlitelimab, showing its ...